Magnus Medical Announces Commercial Launch of Groundbreaking SAINT Neuromodulation System
Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced the commercial launch of the SAINT® neuromodulation system, a groundbreaking, rapid-acting therapy for treatment-resistant major depressive disorder (MDD).
- Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced the commercial launch of the SAINT® neuromodulation system, a groundbreaking, rapid-acting therapy for treatment-resistant major depressive disorder (MDD).
- View the full release here: https://www.businesswire.com/news/home/20240430113478/en/
The commercially available SAINT® neuromodulation system from Magnus Medical provides a new form of individualized neurostimulation therapy for treatment-resistant major depression in adults who have failed to achieve satisfactory improvement from prior antidepressant medications. - The American Medical Association (AMA) issued new Category III Current Procedural Terminology (CPT) codes for targeted, accelerated iTBS for depression, encompassing the SAINT neuromodulation system, effective July 1, 2024.
- Magnus Medical expects to have selective insurance coverage in both the hospital inpatient and outpatient setting and the physician’s office.